Z-005
Zonisamide solution
1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式（希尔记法）:
C8H8N2O3S
化学文摘社编号:
分子量:
212.23
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
EC Number:
200-659-6
MDL number:
产品名称
Zonisamide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
InChI key
UBQNRHZMVUUOMG-UHFFFAOYSA-N
InChI
1S/C8H8N2O3S/c9-14(11,12)5-7-6-3-1-2-4-8(6)13-10-7/h1-4H,5H2,(H2,9,11,12)
SMILES string
NS(CC1=NOC2=C1C=CC=C2)(=O)=O
grade
certified reference material
form
liquid
feature
Snap-N-Spike®/Snap-N-Shoot®
packaging
ampule of 1 mL
manufacturer/tradename
Cerilliant®
concentration
1.0 mg/mL in methanol
technique(s)
gas chromatography (GC): suitable
liquid chromatography (LC): suitable
application(s)
clinical testing
format
single component solution
storage temp.
−20°C
Quality Level
Gene Information
Legal Information
CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Zonegran is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.
General description
Zonisamide is a second-generation anticonvulsant approved for use as an adjunctive therapy in adults with partial-onset seizures, infantile spasm, mixed seizure types of Lennox-Gastaut syndrome, and generalized tonic-clonic seizure. Zonisamide is marketed in the US under the trade name Zonegran®.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1
target_organs
Eyes
存储类别
3 - Flammable liquids
wgk
WGK 2
flash_point_f
49.5 °F - closed cup
flash_point_c
9.7 °C - closed cup
法规信息
危险化学品
此项目有
M J Brodie et al.
Acta neurologica Scandinavica. Supplementum, (194)(194), 19-28 (2012-11-01)
Zonisamide is a benzisoxazole derivative, chemically unrelated to other antiepileptic drugs, that appears to have multiple mechanisms of action, including inhibition of Na(+) channels and reduction of T-type Ca(2+) currents. It is currently licensed in Europe and the USA for
Actigraphic study of tremor before and after treatment with zonisamide in patients with Parkinson's disease.
Soichiro Mochio et al.
Parkinsonism & related disorders, 18(7), 906-908 (2012-05-02)
Michel Baulac et al.
The Lancet. Neurology, 11(7), 579-588 (2012-06-12)
Additional options are needed for monotherapy treatment of adults newly diagnosed with partial epilepsy. This trial compares the efficacy and tolerability of once-daily zonisamide with twice-daily controlled-release carbamazepine monotherapy for such patients. In this phase 3, randomised, double-blind, parallel-group, non-inferiority
Combination therapy of zonisamide with aripiprazole on ECT- and benzodiazepine-resistant periodic catatonia.
Masanori Nakagawa et al.
The Journal of neuropsychiatry and clinical neurosciences, 24(3), E9-E9 (2012-10-06)
Yuto Ueda et al.
Biochemical and biophysical research communications, 428(3), 401-404 (2012-10-30)
The anti-epileptic drug zonisamide is reported to exert beneficial effects in patients with Parkinson's disease. To elucidate the pathophysiological mechanisms underlying the anti-parkinsonism effects of zonisamide, we examined the effect of zonisamide co-administered with levodopa in the striata of rats
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持